PDCD1 and neoplasm: These findings highlight the nuanced interpatient differences in PD-1 inhibitor responses and suggest a model by which B cell clones support the expansion and activation of specific T cell clones in lymph nodes, leading to more effective tumor clearance (Fig. 3H).